Abstracts tagged "gout"

Abstract Number: 2589 • ACR Convergence 2025
Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome
Yuanpiao Ni¹, Fanxin Zeng², Yufeng Qing³ and Quanbo Zhang³, ¹Affiliated Hospital Of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic), ²Dazhou Central Hospital, Dazhou, Sichuan, China (People's Republic), ³The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic)

Background/Purpose: Gout is a metabolic disorder driven by abnormalities in urate metabolism and chronic inflammation. Recent studies suggest that gout is not limited to joint…
Abstract Number: 2003 • ACR Convergence 2025
Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
Julia Buchfuhrer¹, Niranjan Kathe², Elizabeth Ibiloye³, Seth Kuranz⁴, Virginia Noxon-Wood⁴, Alexis Woods⁵ and Laurence Gozalo⁴, ¹JB Arthritis and Rheumatology Center, Downey, CA, ²Amgen Inc, San Diego, CA, ³Amgen Inc, Thousand Oaks, CA, ⁴Inovalon, Bowie, MD, ⁵Amgen, Detroit, MI
Background/Purpose: Among patients (pts) with chronic refractory gout (CRG), traditional urate lowering therapies are often inadequate, necessitating advanced therapies. Pegloticase, a recombinant uricase enzyme, rapidly…
Abstract Number: 1799 • ACR Convergence 2025
Validating the Gouty Arthritis Alleviating Effects of Cerevisterol through Integrated In Silico, In Vitro, and In Vivo Studies
Xiao-Na Ma¹, Mei-Feng Shi¹, Qian Chen¹, Fang-Shu Zou¹, Wei Feng¹, Qing-Ping Liu¹, Chang-Song Lin¹, Nan Li², Xiao-Bao Liu¹ and Qiang Xu¹, ¹Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), ²School of Traditional Chinese Medicine, Jinan University, Guangzhou, China (People's Republic)
Background/Purpose: Zhuling has traditionally been utilized in the treatment of gouty arthritis (GA). Although its therapeutic benefits are recognized, the molecular mechanisms underlying Zhuling's action…
Abstract Number: 1124 • ACR Convergence 2025
ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations
Blanka Stiburkova¹, katerina pavelcova², Jana masinova³, Pavel Jesina⁴, Yu Toyoda⁵ and Tappei Takada⁵, ¹Institute of Rheumatology, Praha ¹⁰, Czech Republic, ²Institute of Rheumatology, Praha ², Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Revmatologický ústav, Praha ², Czech Republic, ⁵The University of Tokyo Hospital, Tokyo, Japan
Background/Purpose: Gout, a condition arising from hyperuricemia, is considered as both a metabolic disorder and an autoinflammatory disease. Genetic factors are estimated to contribute approximately…
Abstract Number: 2588 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies
Angelo Gaffo¹, Herbert Baraf², Anand Patel³, Tuhina Neogi⁴, Rehan Azeem⁵, Wesley DeHaan⁶, Ben Peace⁷, Hugues Santin-Janin⁸, Bhavisha Desai⁹ and Naomi Schlesinger¹⁰, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Boston University School of Medicine, Boston, MA, ⁵Global MACD, Sobi Inc., Waltham, MA, ⁶Sobi, Inc, Waltham, MA, ⁷Statistical Science, Sobi, Stockholm, Sweden, ⁸Sobi, BASEL, Switzerland, ⁹Sobi, Glastonbury, CT, ¹⁰Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Urate-lowering therapy is recommended to lower serum urate (sUA) and for long-term prevention of gout flares (FitzGerald et al. Arthritis Care Res (Hoboken) 2020;…
Abstract Number: 2002 • ACR Convergence 2025
Methods to Address Survival Bias and Competing Risks in Estimating the Causal Risks of Gout on Dementia Risk
Joshua Baker¹, Harlan Sayles², Chung-Chou Chang³, Brian Coburn⁴, Bryant England² and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pittsburgh, Pittsburgh, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Informative censoring in epidemiologic research studies (the loss of data from the risk set that is related to the exposure and/or outcome) can cause…
Abstract Number: 1259 • ACR Convergence 2025
Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
Angelo Gaffo¹, Bhavisha Desai², Abiola Oladapo³, Nana Kragh⁴, Rebekah Zincavage⁵, Brad Padilla⁵ and Naomi Schlesinger⁶, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²Sobi, Glastonbury, CT, ³Sobi INC, Waltham, MA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Stratevi, Boston, ⁶Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Many patients with uncontrolled gout (UG) experience symptoms despite being on urate-lowering therapy (ULT), often requiring support from informal caregivers. UG impacts patients and…
Abstract Number: 1123 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Alan Kivitz¹, Atul Singhal², Anand Patel³, Rehan Azeem⁴, Ben Peace⁵, Bhavisha Desai⁶ and Herbert Baraf⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²SouthWest Arthritis Research Group, Mesquite, TX, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Statistical Science, Sobi, Stockholm, Sweden, ⁶Sobi, Glastonbury, CT, ⁷The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC
Background/Purpose: Uncontrolled gout (UG) occurs when serum uric acid (sUA) levels remain persistently elevated despite use of oral urate-lowering therapies and can result in progressively…
Abstract Number: 2587 • ACR Convergence 2025
Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
Puja Khanna¹, Amar Majjhoo², Rehan Azeem³, Ben Peace⁴, Bhavisha Desai⁵ and Vibeke Strand⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Shores Rheumatology, St. Clair Shores, MI, ³Global MACD, Sobi Inc., Waltham, MA, ⁴Statistical Science, Sobi, Stockholm, Sweden, ⁵Sobi, Glastonbury, CT, ⁶Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Patients (pts) with uncontrolled gout (UG; persistent elevation in serum uric acid [sUA] levels and clinical manifestations despite oral urate-lowering therapy) have poor health-related…
Abstract Number: 2001 • ACR Convergence 2025
Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use
Jason Yang¹, Ted Mikuls², Harlan Sayles², Michael Pillinger³, Jeff Newcomb², Bridget Kramer², Anne Davis-Karim⁴, Mary Brophy⁵, Ryan Ferguson⁵, Paul Palevsky⁶, James O'Dell² and Tuhina Neogi⁷, ¹Boston Medical Center, Boston, MA, ²University of Nebraska Medical Center, Omaha, NE, ³New York University Grossman School of Medicine, New York,, NY, ⁴VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁵VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁶VA Pittsburgh Healthcare System, Pittsburgh, PA, ⁷Boston University School of Medicine, Boston, MA
Background/Purpose: Gout flares are an important treatment outcome in gout. Although flares are typically assessed by occurrence (yes/no) or a simple count in trials of…
Abstract Number: 1146 • ACR Convergence 2025
Association of Walking Volume and Intensity With Incident Gout: A Population-based Cohort Study
Ziying Wu¹, Ying Hu², Hongyi He³, Yuqing Zhang⁴, Nicola Dalbeth⁵, Junqing xie⁶, Yilun Wang⁷, Chao Zeng⁷, Guanghua Lei⁷ and Jie Wei⁷, ¹Xiangya Hospital, Central South University, Chang Sha, China (People's Republic), ²Xiangya School of Public Health Central South University, changsha, China (People's Republic), ³Xiangya Hospital Central South University, Changsha, China (People's Republic), ⁴Massachusetts General Hospital, Harvard Medical School, Boston, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Oxford, Oxford, ⁷Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic)
Background/Purpose: Previous studies have reported that walking is associated with a lower risk of several metabolic diseases; however, evidence of its association with gout, a…
Abstract Number: 1076 • ACR Convergence 2025
Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Arthur Lau⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Although achieving target serum urate (SU) and reducing cardiovascular events are cornerstones of gout management, little is known about contemporary treatment patterns across racial…
Abstract Number: 2586 • ACR Convergence 2025
Estimated Carrier Prevalence of HLA-B*58:01 Across Diverse Populations in the US and Globally
Qiping Xu¹, Joan Bathon² and Yiming Luo², ¹Mayo Clinic, Mankato, ²Columbia University, NEW YORK, NY
Background/Purpose: The HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions. The 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout…
Abstract Number: 1999 • ACR Convergence 2025
Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials
Herbert Baraf¹, Andrew J. Sulich², Guillermo J. Valenzuela³, Rehan Azeem⁴, Ben Peace⁵, Bhavisha Desai⁶ and Puja Khanna⁷, ¹The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ²Shores Rheumatology, St. Clair Shores, MI, ³Iris Rheumatology, Plantation, FL, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Statistical Science, Sobi, Stockholm, Sweden, ⁶Sobi, Glastonbury, CT, ⁷Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Uricase-based therapies may profoundly lower serum uric acid (sUA) in patients (pts) with uncontrolled gout (UG) but often lead to anti-drug antibody (ADA) formation,…
Abstract Number: 1144 • ACR Convergence 2025
A quantitative study of renal medulla echogenicity in 250 Vietnames gout patients shows correlation with poor renal function
Thomas Bardin¹, Quang Nguyen², anouk Walter-Petrich³, Khoi Minh Tran², Duong Ba Pham², Quang Huy Nguyen⁴, Chuc Van Tran², Day Phuoc Huynh², Minh Do⁵, Emmanuel Letavernier⁶, richette pascal⁷, Matthieu Resche-Rigon³ and Jean-Michel Correas⁸, ¹Lariboisiere Hospital, Department of Rheumatology, Paris, France, ²Vien Gut Medical centre, Ho Chi Minh City, Vietnam, ³UMR U¹³⁴² ECSTRA team INERM, Université Paris Cité, Paris, France, ⁴Vien Gut Medicfal Centre, Ho Chi Minh City, ⁵University of Medicine and Pharmacy at Ho Chi Min City, Ho Chi Minh City, Vietnam, ⁶Sorbonne Université and INSERM, UMR S ¹¹⁵⁵, Hôpital Tenon, Paris, France, ⁷Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ⁸Department of Radiology, NeckerUniversity Hospital, Paris, France
Background/Purpose: We previously described the frequent occurrence of an hyperechogenic pattern of the renal medulla following crystal deposition in untreated Vietnamese patients with severe tophaceous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].